Skip to Main Content
Contact Us

ASCO 2022 Conference Review: Exciting New Developments and Trends

Headshot of Andrew Zupnick
Andrew Zupnick, PhD
July 08, 2022 4 min read

Catalyst Oncology strives to stay at the forefront of new developments in the industry; when it comes to cancer care, we believe that every second counts. That is why we were delighted to be back in person at the annual American Society of Clinical Oncology (ASCO) conference … and it certainly didn’t disappoint.

After two years of virtual meetings, McCormick Place was buzzing with energy. With vaccine requirements and COVID safety protocols in place, nearly 40,000 attendees were ready to bump elbows, shake hands, or hug, looking to rebuild bonds of friendship missed in years past. 

People were respectful and understanding, allowing everyone to navigate their own way through a large event in a post COVID world. Many of us were a bit rusty after 2 years of video calls and comfy clothes, myself included, where I made a “rookie mistake” of logging 20,000 steps in new shoes that hadn’t been broken in (thank you Catalyst Marketing team for saving the day with some bandages!).

There were over 5000 abstracts at the event with hundreds of presentations, making it impossible to attend all sessions.  That said, some potentially life-changing treatments were on display, and here are some highlights from the meeting:

These are just a few of the highlights from ASCO 2022 that signal progress for the oncology drug development industry.  With so many rare, biomarker-driven, and immuno-oncology treatments in development, the future is bright for the promise of finally moving away toxic treatments into the world of highly personalized and long-term care.